Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04591431
Title	The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME)
Acronym	ROME
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Fondazione per la Medicina Personalizzata
Indications	gastrointestinal system cancer lung non-small cell carcinoma breast cancer Advanced Solid Tumor
Therapies	Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib
Age Groups:	adult \| senior
Covered Countries	ITA